Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALEPRO: abemaciclib + letrozole in estrogen receptor-positive rare ovarian cancer
NL-OMON59615Phase 2Recruiting
- Sponsor
- UZ Leuven
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, letrozole in low-grade serous ovarian carcinoma (LGSOC), granulosa cell tumor (GCT), Endometrioid Cystadenocarcinoma, sponsored by UZ Leuven. Started Feb 2025; status: recruiting.
02
Drugs
abemaciclibletrozole
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)granulosa cell tumor (GCT)Endometrioid Cystadenocarcinoma
Beyond the preview
Go deeper on NL-OMON59615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59615.